IFRX
Price
$1.53
Change
-$0.02 (-1.29%)
Updated
Oct 22 closing price
Capitalization
225.47M
17 days until earnings call
Intraday BUY SELL Signals
VIR
Price
$10.43
Change
-$0.14 (-1.32%)
Updated
Oct 22 closing price
Capitalization
1.76B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IFRX vs VIR

IFRX vs VIR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IFRX vs. VIR commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IFRX is a Buy and VIR is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IFRX with price predictions
Oct 22, 2026

IFRX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for IFRX turned positive on October 21, 2026. Looking at past instances where IFRX's MACD turned positive, the stock continued to rise in 44 of 50 cases over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IFRX's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 63 of 74 cases where IFRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on IFRX as a result. In 84 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

Following a +6.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where IFRX advanced for three days, in 185 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

IFRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

IFRX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for IFRX crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 20 of 24 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IFRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for IFRX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.542) is normal, around the industry mean (2.973). P/E Ratio (-3.060) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. IFRX's P/S Ratio (3333.333) is slightly higher than the industry average of (438.009).

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IFRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IFRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VIR with price predictions
Oct 22, 2026

VIR in downward trend: 10-day moving average moved below 50-day moving average on October 22, 2026

The 10-day moving average for VIR crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIR as a result. In 70 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for VIR turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 34 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

VIR moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 59 cases where VIR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.

Following a +7.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIR advanced for three days, in 202 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

VIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 120 of 159 cases where VIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.796) is normal, around the industry mean (2.973). P/E Ratio (-5.893) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (5.168) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. VIR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IFRX vs VIR: Fundamental Ratings
IFRX
VIR
OUTLOOK RATING
1..100
6562
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
6342
P/E GROWTH RATING
1..100
2457
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IFRX's Valuation (2) in the Biotechnology industry is in the same range as VIR (23) in the null industry. This means that IFRX’s stock grew similarly to VIR’s over the last 12 months.

IFRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as VIR (100) in the null industry. This means that IFRX’s stock grew similarly to VIR’s over the last 12 months.

VIR's SMR Rating (96) in the null industry is in the same range as IFRX (97) in the Biotechnology industry. This means that VIR’s stock grew similarly to IFRX’s over the last 12 months.

VIR's Price Growth Rating (42) in the null industry is in the same range as IFRX (63) in the Biotechnology industry. This means that VIR’s stock grew similarly to IFRX’s over the last 12 months.

IFRX's P/E Growth Rating (24) in the Biotechnology industry is somewhat better than the same rating for VIR (57) in the null industry. This means that IFRX’s stock grew somewhat faster than VIR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IFRXVIR
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
68%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
Bearish Trend 8 days ago
87%
Bearish Trend 1 day ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
71%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
75%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (IFRX: $1.53 vs. VIR: $10.43)
Brand notoriety: IFRX and VIR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IFRX: 51% vs. VIR: 47%
Market capitalization -- IFRX: $225.47M vs. VIR: $1.76B
IFRX [@Biotechnology] is valued at $225.47M. VIR’s [@Biotechnology] market capitalization is $1.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IFRX’s FA Score shows that 2 FA rating(s) are green while VIR’s FA Score has 1 green FA rating(s).

  • IFRX’s FA Score: 2 green, 3 red.
  • VIR’s FA Score: 1 green, 4 red.
According to our system of comparison, both IFRX and VIR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IFRX’s TA Score shows that 6 TA indicator(s) are bullish while VIR’s TA Score has 4 bullish TA indicator(s).

  • IFRX’s TA Score: 6 bullish, 4 bearish.
  • VIR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, IFRX is a better buy in the short-term than VIR.

Price Growth

IFRX (@Biotechnology) experienced а +6.25% price change this week, while VIR (@Biotechnology) price change was -0.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

IFRX is expected to report earnings on Nov 09, 2026.

VIR is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IFRX
Daily Signal:
Gain/Loss:
VIR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

IFRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IFRX has been loosely correlated with KURA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if IFRX jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IFRX
1D Price
Change %
IFRX100%
-1.29%
KURA - IFRX
40%
Loosely correlated
-0.20%
VIR - IFRX
37%
Loosely correlated
-1.32%
SGMT - IFRX
36%
Loosely correlated
-0.40%
DSGN - IFRX
36%
Loosely correlated
-2.24%
FDMT - IFRX
35%
Loosely correlated
-6.10%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CZA124.791.62
+1.31%
Invesco Zacks Mid-Cap ETF (CZA)
SMBS24.470.19
+0.76%
Schwab Mortgage-Backed Securities ETF (SMBS)
PSK28.050.12
+0.43%
State Street SPDR ICE Preferred Securities ETF (PSK)
XCNY32.37-0.90
-2.69%
State Street SPDR S&P Emerging Markets ex-China ETF (XCNY)
QQQT17.10-0.50
-2.83%
Defiance Nasdaq 100 Income Target ETF (QQQT)